Company intelligence / Profile preview

LumaCyte

Charlottesville, Virginia, United Stateslumacyte.com ↗

Ownership: Private
Development stage: Other

Overview

LumaCyte’s Laser Force Cytology™ platform enables label-free single-cell analysis for real-time bioprocess monitoring and quality control in advanced therapies. The technology supports applications such as viral infectivity assays for vaccine development/manufacturing, CAR T-cell immunotherapy analytics, iPSC differentiation monitoring, AAV transfection/transduction analysis for gene therapy production optimization. No clinical trial results as the company provides instrumentation rather than therapeutics.

Therapeutic areas: Other
Modalities: Device (bioanalytical instrumentation)Platform technology for cell and gene therapy analytics
Industry: Non-Drug Biotech

Partnerships

Malvern Panalytical (strategic investor/partner)

Beyond the preview

Go deeper on LumaCyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LumaCyte.

Explore the full profile